RU2175229C2 - Анксиолитическое средство - Google Patents
Анксиолитическое средство Download PDFInfo
- Publication number
- RU2175229C2 RU2175229C2 RU99127550/14A RU99127550A RU2175229C2 RU 2175229 C2 RU2175229 C2 RU 2175229C2 RU 99127550/14 A RU99127550/14 A RU 99127550/14A RU 99127550 A RU99127550 A RU 99127550A RU 2175229 C2 RU2175229 C2 RU 2175229C2
- Authority
- RU
- Russia
- Prior art keywords
- mice
- anxiolytic
- effect
- ladasten
- activity
- Prior art date
Links
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (1)
- Применение (адамант-2-ил)-(пара-бромфенил)амина (ладастена) в качестве анксиолитического средства.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU99127550/14A RU2175229C2 (ru) | 1999-12-22 | 1999-12-22 | Анксиолитическое средство |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU99127550/14A RU2175229C2 (ru) | 1999-12-22 | 1999-12-22 | Анксиолитическое средство |
Publications (2)
Publication Number | Publication Date |
---|---|
RU99127550A RU99127550A (ru) | 2001-09-10 |
RU2175229C2 true RU2175229C2 (ru) | 2001-10-27 |
Family
ID=20228716
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU99127550/14A RU2175229C2 (ru) | 1999-12-22 | 1999-12-22 | Анксиолитическое средство |
Country Status (1)
Country | Link |
---|---|
RU (1) | RU2175229C2 (ru) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3817749A4 (en) * | 2018-07-06 | 2022-05-04 | Algernon Pharmaceuticals Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS |
-
1999
- 1999-12-22 RU RU99127550/14A patent/RU2175229C2/ru active
Non-Patent Citations (1)
Title |
---|
МОРОЗОВ И.С. и др. Влияние бромантана на физическую работоспособность лабораторных животных. Экспериментальная и клиническая фармакология. 1998, № 6, с.51-53. * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3817749A4 (en) * | 2018-07-06 | 2022-05-04 | Algernon Pharmaceuticals Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Barnes et al. | Chronic treatment of old rats with donepezil or galantamine: effects on memory, hippocampal plasticity and nicotinic receptors | |
Rivat et al. | Chronic stress induces transient spinal neuroinflammation, triggering sensory hypersensitivity and long-lasting anxiety-induced hyperalgesia | |
Sathiya et al. | Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice | |
Donnan et al. | Motor function in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-treated mouse | |
Filali et al. | Subchronic memantine administration on spatial learning, exploratory activity, and nest-building in an APP/PS1 mouse model of Alzheimer’s disease | |
Rex et al. | Anxiolytic-like effects of Kava-Kava in the elevated plus maze test—a comparison with diazepam | |
Vorhees et al. | Periadolescent rats (P41–50) exhibit increased susceptibility to D-methamphetamine-induced long-term spatial and sequential learning deficits compared to juvenile (P21–30 or P31–40) or adult rats (P51–60) | |
US9271974B2 (en) | Use of oxycodone for treating visceral pain | |
Carey et al. | SCH 57790, a selective muscarinic M2 receptor antagonist, releases acetylcholine and produces cognitive enhancement in laboratory animals | |
Spindola et al. | The antinociceptive activity of harmicine on chemical-induced neurogenic and inflammatory pain models in mice | |
Stemmelin et al. | Sensitivity to cholinergic drug treatments of aged rats with variable degrees of spatial memory impairment | |
Costall et al. | The importance of the ascending dopaminergic systems to the extrapyramidal and mesolimbic brain areas for the cataleptic action of the neuroleptic and cholinergic agents | |
Meunier et al. | Attenuation by a sigma1 (σ1) receptor agonist of the learning and memory deficits induced by a prenatal restraint stress in juvenile rats | |
Ranjbar et al. | Angiotensin II type 1 receptor blocker losartan attenuates locomotor, anxiety-like behavior, and passive avoidance learning deficits in a sub-chronic stress model | |
Moragrega et al. | Spatial learning in male mice with different levels of aggressiveness: effects of housing conditions and nicotine administration | |
Micheli et al. | Pain relieving and neuroprotective effects of non-opioid compound, DDD-028, in the rat model of paclitaxel-induced neuropathy | |
Möbius | Memantine: update on the current evidence | |
Itoh et al. | Effects of metrifonate on memory impairment and cholinergic dysfunction in rats | |
WO2017108441A1 (en) | Treatment of cognitive impairment with cgc stimulator | |
Block et al. | Dextromethorphan reduces functional deficits and neuronal damage after global ischemia in rats | |
Eliav et al. | The kappa opioid agonist GR89 696 blocks hyperalgesia and allodynia in rat models of peripheral neuritis and neuropathy | |
RU2175229C2 (ru) | Анксиолитическое средство | |
De Bruin et al. | Attentional performance of (C57BL/6J× 129Sv) F2 mice in the five-choice serial reaction time task | |
Meunier et al. | Beneficial effects of the sigma1 receptor agonists igmesine and dehydroepiandrosterone against learning impairments in rats prenatally exposed to cocaine | |
Grasing et al. | Behavioral measures of anxiety during opiate withdrawal |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
QB4A | Licence on use of patent |
Effective date: 20070119 |
|
QB4A | Licence on use of patent |
Effective date: 20070605 |
|
QB4A | Licence on use of patent |
Effective date: 20070912 |
|
PD4A | Correction of name of patent owner | ||
QZ41 | Official registration of changes to a registered agreement (patent) |
Free format text: LICENCE FORMERLY AGREED ON 20070119 Effective date: 20110610 |
|
QZ41 | Official registration of changes to a registered agreement (patent) |
Free format text: SUB-LICENCE FORMERLY AGREED ON 20070912 Effective date: 20111020 |
|
PD4A | Correction of name of patent owner | ||
QZ41 | Official registration of changes to a registered agreement (patent) |
Free format text: LICENCE FORMERLY AGREED ON 20070119 Effective date: 20120827 |
|
PD4A | Correction of name of patent owner | ||
QZ41 | Official registration of changes to a registered agreement (patent) |
Free format text: LICENCE FORMERLY AGREED ON 20070119 Effective date: 20171128 |